You are here: Urology Textbook > Drugs in Urology > Alpha blocker > Alfuzosin

Alfuzosin: Side Effects and Dosage

Mechanism of Action of Alfuzosin

Alfuzosin is a nonselective α₁-blocker with short elimination half-life; sustained-release formulation is available. Please see section general pharmacology of alpha blocker. Review Literatur: (Chapple, 2004).

**Structural formula of Alfuzosin**

Indications for Alfuzosin

Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Off-label treatment of female LUTS due to neurogenic bladder neck obstruction.
Off-label treatment: improve the spontaneous passage of distal ureteral stones.

Pharmacokinetics of Alfuzosin

Elimination half-life: 9 h for the sustained-release formulation.

Side Effects

Increased side effect profile, since alfuzosin is a nonselective α1 blocker.

Initial hypotension, orthostatic collapse, reflex tachycardia, usually transient.
Increased risk (HR 1,2) of cardiac failure in patients with cardiac comorbidity (Lusty et al., 2021).
Stuffy nose
Retrograde ejaculation
Dizziness, weakness.

Contraindications of Alfuzosin

Urological Contraindications:

Conservative treatment of BPH is not indicated if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections, and bladder stones.

Cardiac Contraindications:

Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.

Other contraindications:

Alfuzosin should be paused for cataract surgery to prevent an intraoperative floppy iris syndrome.

Dosage of Alfuzosin

10 mg in retarded galenic formulation orally once daily or 5 mg 1–0–1. The initial or single dose should be given before bedtime in the evening to reduce side effects.

Doxazosin

Index

Silodosin

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Chapple 2004 CHAPPLE, C. R.: Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44

J. Nordling, “Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia,” BJU Int, vol. 95, no. 7, pp. 1006–12, 2005.

Deutsche Version: Alfuzosin